Cargando…
The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation
Background: The main dietary source of omega-3 polyunsaturated fatty acids (n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In the present manuscript, we aimed to review the current evidence regarding the clinical role of n-3 PUFA in the prevention of at...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613340/ https://www.ncbi.nlm.nih.gov/pubmed/26402674 http://dx.doi.org/10.3390/ijms160922870 |
_version_ | 1782396263717666816 |
---|---|
author | Christou, Georgios A. Christou, Konstantinos A. Korantzopoulos, Panagiotis Rizos, Evangelos C. Nikas, Dimitrios N. Goudevenos, John A. |
author_facet | Christou, Georgios A. Christou, Konstantinos A. Korantzopoulos, Panagiotis Rizos, Evangelos C. Nikas, Dimitrios N. Goudevenos, John A. |
author_sort | Christou, Georgios A. |
collection | PubMed |
description | Background: The main dietary source of omega-3 polyunsaturated fatty acids (n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In the present manuscript, we aimed to review the current evidence regarding the clinical role of n-3 PUFA in the prevention of atrial fibrillation (AF) and the possible underlying mechanisms. Methods: A literature search based on PubMed listings was performed using “Omega-3 fatty acids” and “atrial fibrilation” as key search terms. Results: n-3 PUFA have been shown to attenuate structural atrial remodeling, prolong atrial effective refractory period through the prevention of reentry and suppress ectopic firing from pulmonary veins. Dietary fish intake has been found to have no effect on the incidence of AF in the majority of studies. Circulating DHA has been consistently reported to be inversely associated with AF risk, whereas EPA has no such effect. The majority of studies investigating the impact of n-3 PUFA supplementation on the incidence of AF following cardiac surgery reported no benefit, though most of them did not use n-3 PUFA pretreatment for adequate duration. Studies using adequate four-week pretreatment with n-3 PUFA before cardioversion of AF showed a reduction of the AF incidence. Conclusions: Although n-3 PUFA have antiarrhythmogenic properties, their clinical efficacy on the prevention of AF is not consistently supported. Further well-designed studies are needed to overcome the limitations of the existing studies and provide robust conclusions. |
format | Online Article Text |
id | pubmed-4613340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-46133402015-10-26 The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation Christou, Georgios A. Christou, Konstantinos A. Korantzopoulos, Panagiotis Rizos, Evangelos C. Nikas, Dimitrios N. Goudevenos, John A. Int J Mol Sci Review Background: The main dietary source of omega-3 polyunsaturated fatty acids (n-3 PUFA) is fish, which contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). In the present manuscript, we aimed to review the current evidence regarding the clinical role of n-3 PUFA in the prevention of atrial fibrillation (AF) and the possible underlying mechanisms. Methods: A literature search based on PubMed listings was performed using “Omega-3 fatty acids” and “atrial fibrilation” as key search terms. Results: n-3 PUFA have been shown to attenuate structural atrial remodeling, prolong atrial effective refractory period through the prevention of reentry and suppress ectopic firing from pulmonary veins. Dietary fish intake has been found to have no effect on the incidence of AF in the majority of studies. Circulating DHA has been consistently reported to be inversely associated with AF risk, whereas EPA has no such effect. The majority of studies investigating the impact of n-3 PUFA supplementation on the incidence of AF following cardiac surgery reported no benefit, though most of them did not use n-3 PUFA pretreatment for adequate duration. Studies using adequate four-week pretreatment with n-3 PUFA before cardioversion of AF showed a reduction of the AF incidence. Conclusions: Although n-3 PUFA have antiarrhythmogenic properties, their clinical efficacy on the prevention of AF is not consistently supported. Further well-designed studies are needed to overcome the limitations of the existing studies and provide robust conclusions. MDPI 2015-09-22 /pmc/articles/PMC4613340/ /pubmed/26402674 http://dx.doi.org/10.3390/ijms160922870 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Christou, Georgios A. Christou, Konstantinos A. Korantzopoulos, Panagiotis Rizos, Evangelos C. Nikas, Dimitrios N. Goudevenos, John A. The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation |
title | The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation |
title_full | The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation |
title_fullStr | The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation |
title_full_unstemmed | The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation |
title_short | The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation |
title_sort | current role of omega-3 fatty acids in the management of atrial fibrillation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613340/ https://www.ncbi.nlm.nih.gov/pubmed/26402674 http://dx.doi.org/10.3390/ijms160922870 |
work_keys_str_mv | AT christougeorgiosa thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT christoukonstantinosa thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT korantzopoulospanagiotis thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT rizosevangelosc thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT nikasdimitriosn thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT goudevenosjohna thecurrentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT christougeorgiosa currentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT christoukonstantinosa currentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT korantzopoulospanagiotis currentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT rizosevangelosc currentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT nikasdimitriosn currentroleofomega3fattyacidsinthemanagementofatrialfibrillation AT goudevenosjohna currentroleofomega3fattyacidsinthemanagementofatrialfibrillation |